Table 3.

Patient survival and predictors of death at 30 days

	Deaths at 30 days n (%)	Odds Ratio* (95% CI)	p-value*	Odds Ratio+ (95% CI)	p-value+
Etanercept (n=26)	9 (34.6%)	1.8 (0.5,6.5)	0.37
Placebo (n=22)	5 (22.7%)	1.0 (reference)
Age at enrollment		1.6 (0.8,3.4)	0.21	1.6 (0.4,5.9)	0.50
Male gender		0.9 (0.2,3.6)	0.88	1.8 (0.5,6.5)	0.37
Drinks/drinking day		1.0 (0.9,1.1)	0.78	1.8 (0.5,6.5)	0.39
Years of reported alcohol use		1.0 (0.95,1.1)	0.69	1.7 (0.4,6.8)	0.48
Enrollment MELD		1.1 (0.97,1.2)	0.17	1.7 (0.5,6.4)	0.41
Albumin		0.4 (0.1,1.8)	0.22	1.2 (0.3,5.8)	0.81
Ascites		2.6 (0.7,9.3)	0.15	1.5 (0.4,5.7)	0.53
Hepatic Encephalopathy		0.6 (0.1,5.7)	0.64	1.9 (0.5,7.1)	0.32

^*Univariate model, odds ratio for death (<=30 days).

⁺Odds Ratio for death (<=30 days) in patient receiving etanercept (relative to Placebo), adjusting for indicated variable (age, gender, etc).